Overexpression of MLPH in Rectal Cancer Patients Correlates with a Poorer Response to Preoperative Chemoradiotherapy and Reduced Patient Survival

doi:10.3390/diagnostics11112132

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/34342

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34342

Title:	Overexpression of MLPH in Rectal Cancer Patients Correlates with a Poorer Response to Preoperative Chemoradiotherapy and Reduced Patient Survival
Authors:	Li, Wan-Shan Chen, Chih-, I Chen, Hsin-Pao Liu, Kuang-Wen Tsai, Chia-Jen Yang, Ching-Chieh
Contributors:	Natl Sun Yat Sen Univ, Inst Biomed Sci Chi Mei Med Ctr, Dept Pathol Chung Hwa Univ Med Technol, Dept Med Technol E DA Hosp, Dept Surg, Div Colon & Rectal Surg E DA Hosp, Dept Surg, Div Gen Med Surg I Shou Univ, Sch Med, Dept Med I Shou Univ, Dept Informat Engn I Shou Univ, Sch Chinese Med Post Baccalaureate Chi Mei Med Ctr, Dept Radiat Oncol Chia Nan Univ Pharm & Sci, Dept Pharm
Keywords:	melanophilin rectal cancer chemoradiotherapy response survival
Date:	2021
Issue Date:	2023-11-11 11:44:44 (UTC+8)
Publisher:	MDPI
Abstract:	Data mining of a public transcriptomic rectal cancer dataset (GSE35452) from the Gene Expression Omnibus, National Center for Biotechnology Information identified the melanophilin (MLPH) gene as the most significant intracellular protein transport-related gene (GO:0006886) associated with a poor response to preoperative chemoradiation. An MLPH immunostain was performed on biopsy specimens from 172 rectal cancer patients receiving preoperative chemoradiation; samples were divided into high- and low-expression groups by H-scores. Subsequently, the correlations between MLPH expression and clinicopathologic features, tumor regression grade, disease-specific survival (DSS), local recurrence-free survival (LRFS), and metastasis-free survival (MeFS) were analyzed. MLPH expression was significantly associated with CEA level (p = 0.001), pre-treatment tumor status (p = 0.022), post-treatment tumor status (p < 0.001), post-treatment nodal status (p < 0.001), vascular invasion (p = 0.028), and tumor regression grade (p < 0.001). After uni- and multi-variable analysis of five-year survival, MLPH expression was still associated with lower DSS (hazard ratio (HR), 10.110; 95% confidence interval (CI), 2.178-46.920; p = 0.003) and MeFS (HR, 5.621; 95% CI, 1.762-17.931; p = 0.004). In conclusion, identifying MLPH expression could help to predict the response to chemoradiation and survival, and aid in personal therapeutic modification.
Relation:	DIAGNOSTICS, v.11, n.11, pp.2132
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
diagnostics11112132.pdf		2671Kb	Adobe PDF	134	View/Open
index.html		0Kb	HTML	169	View/Open

Loading...